A4. CONCLD.

~~88-89~~. (New) The method of claim ~~76~~ 15, wherein said antibody is heat-treated prior to administration.

REMARKS

By this amendment, claims 1-61 have been cancelled and new claims 62-89 submitted. Support for the above claims is found in the specification on page 20, lines 12-17; page 21, lines 11-17; page 60, lines 9-14; page 61, lines 4-7; page 63, line 15, to page 64, line 5; Example 5.

Regarding the amendments to the specification and the figures, The parent application and the application filed herewith contain an error in the heavy chain variable region protein sequence. By way of this amendment, the heavy chain protein sequence data is corrected, and related figures and commentary are adjusted accordingly.

Please note that these amendments were considered and entered in the parent appliction, serial number 08/752,844. Also accompanying this amendment is a copy of a signed declaration by Dr. Sunil Chatterjee, which was submitted October 7, 1997, in the parent application, explaining how the error was inadvertenly introuced into the amino acid sequence in Figure 2.

The amendments to the specification and the figures do not constitute new matter for two reasons: 1) The protein sequence data is a translation of the encoding sequence which was obtained first and correctly represented in the parent application; 2) The protein sequence is inherent in the deposit of the 1A7 antibody producing cell, deposited in support of the present application and its parent.

The error in the heavy chain protein sequence occurs at position 106. Tryptophan ("W") is indicated incorrectly instead of tyrosine ("Y"). This is depicted in Figure 2 of the application as originally filed at the last amino acid residue of the CDR-3 region.

Example 2 of the specification describes that the nucleotide was obtained first by PCR amplification of mRNA from the 1A7 producing cell line (page 79, line 2 to page 80, line 14). The N-terminal amino acid sequence was confirmed by sequencing the first 10-15 amino acids (page 80, line 15 to page 81, line 6). The rest of the amino acid sequence reported in Figure 2 is the corresponding translation of the nucleic acid sequence (page 81, lines 7-8). The error in Figure 2 is an error in translation of the correct nucleic acid sequence.

It is obvious to a practitioner of ordinary skill in the art that tyrosine is the correct amino acid translation at this position: the corresponding polynucleotide encoding sequence is the codon "TAC", which unambiguously translates to tyrosine.

The correct amino acid sequence can also be confirmed by reference to the 1A7 antibody or the encoding sequence prepared from the hybridoma deposited under ATCC Accession No. HB-11786 (page 23, line 7). The amino acid sequence is inherent in the 1A7 antibody sequence. The deposit was made with the ATCC before the filing of the present application or its parent, and constitutes part of the disclosure.

The requested amendments correct errors in the specification resulting from the inadvertent error in the translation indicated for this position in Figure 2. By way of this amendment, the translation in Figure 2 is amended to replace the amino acid translation above the codon at position 106 with tyrosine. The identity analysis shown in Figure 3(B) and the heavy chain consensus analysis shown in Figure 3(C) respectively ensue from comparing the 1A7 heavy chain amino acid sequence with reference sequences obtained from GenBank, or a consensus thereof. By way of this amendment, Figure 3(B) is corrected to reflect the correct 1A7 sequence, and the tyrosine ("Y") at the corresponding position of the sequences being compared should be marked as identical ("."). Figure 3(C) is corrected to reflect that 1A7 is identical to the consensus sequence at this position ("."). The commentary on pages 12 and 85-86 ensues by counting the differences between the 1A7 heavy chain amino acid sequence and sequences obtained from GenBank. By way of this amendment, the commentary on pages 12 and 85-86 is corrected with respect to the exact number of differences between the 1A7 sequence and the other sequences referred to. All these corrections are obvious in light of the correct 1A7 heavy chain amino acid sequence.

Entry of these amendments is requested for the convenience of the reader.

If there are any aspect of this amendment the Examiner wishes to discuss, the Examiner is invited to telephone Applicants' representative at the telephone number below.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 304142000201. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 15, 1999

By: 

Catherine M. Polizzi
Registration No. 40,130

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5651
Facsimile: (650) 494-0792